1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: First Line Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Exemestane
Sponsor: ARCAGY/ GINECO GROUP